melatonin has been researched along with Lung Neoplasms in 65 studies
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Patients with stage IIIB or IV lung adenocarcinoma, who had progressed after prior standard chemotherapy, and with an Eastern Cooperative Oncology Group PS > or = 2, received a daily combination of somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide." | 9.12 | Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. ( Martino, V; Norsa, A, 2007) |
| " The study was performed in 14 metastatic breast cancer women treated by weekly epirubicin." | 9.09 | Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| " In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone." | 9.07 | A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994) |
| "Overall, the patients with newly diagnosed lung cancer had poorer sleep quality, higher depression levels, lower salivary melatonin levels, higher cortisol levels, and flatter melatonin and cortisol slopes than did the controls." | 7.85 | Relationships of salivary cortisol and melatonin rhythms to sleep quality, emotion, and fatigue levels in patients with newly diagnosed lung cancer. ( Chang, WP; Lin, CC, 2017) |
| "On the basis of the demonstrated existence of immunoneuroendocrine interactions and on the previously observed synergistic action between the pineal hormone melatonin (MLT) and interleukin-2 (IL-2), we have designed a neuroimmunotherapeutic combination consisting of low-dose IL-2 and MLT in the treatment of advanced solid neoplasms." | 7.68 | Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. ( Ardizzoia, A; Barni, S; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rovelli, F; Tancini, G, 1993) |
| "The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology." | 6.69 | Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. ( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998) |
| "Melatonin is a hormone synthesized in the pineal gland and has widespread physiological and pharmacological functions." | 5.72 | Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. ( Duan, H; Duan, W; Li, X; Lu, G; Shao, C; Wang, J; Wang, Y; Wang, Z; Xie, M; Yan, X; Yu, W, 2022) |
| "Melatonin treatment also influenced the expression of HDAC-related molecules (HDAC1 and Ac-histone H3), upregulated the apoptosis-related molecules (PUMA and Bax), and downregulated the proliferation-related molecule (PCNA) and the anti-apoptosis-related molecule (Bcl2)." | 5.42 | HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways. ( Di, S; Fan, C; Jiang, S; Li, T; Li, W; Li, X; Ma, Z; Pan, Y; Reiter, RJ; Yan, X; Yang, Y; Zhang, Z, 2015) |
| "Melatonin was tested on the cell line only after 24 h incubation (direct effect), and on the co-culture system of SK-LU-1 and PBMC to investigate any indirect effect." | 5.40 | Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells. ( Barusrux, S; Johns, NP; Khamphio, M; Plaimee, P; Weerapreeyakul, N, 2014) |
| "Thrombocytopenia is a frequent haematologic complication of IL-2 immunotherapy of cancer." | 5.29 | Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin. ( Barni, S; Bregani, ER; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rossini, F; Tancini, G, 1995) |
| "Patients with stage IIIB or IV lung adenocarcinoma, who had progressed after prior standard chemotherapy, and with an Eastern Cooperative Oncology Group PS > or = 2, received a daily combination of somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide." | 5.12 | Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status. ( Martino, V; Norsa, A, 2007) |
| " The study was performed in 14 metastatic breast cancer women treated by weekly epirubicin." | 5.09 | Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study. ( Ardizzoia, A; Barni, S; Giani, L; Lissoni, P; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G, 1999) |
| " In particular, the association with the pineal neurohormone melatonin (MLT) has been shown to cause tumour regressions in neoplasms that are generally non-responsive to IL-2 alone." | 5.07 | A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. ( Aldeghi, R; Ardizzoia, A; Barni, S; Brivio, F; Lissoni, P; Rescaldani, R; Ricci, G; Rovelli, F; Tancini, G; Tisi, E, 1994) |
| "Overall, the patients with newly diagnosed lung cancer had poorer sleep quality, higher depression levels, lower salivary melatonin levels, higher cortisol levels, and flatter melatonin and cortisol slopes than did the controls." | 3.85 | Relationships of salivary cortisol and melatonin rhythms to sleep quality, emotion, and fatigue levels in patients with newly diagnosed lung cancer. ( Chang, WP; Lin, CC, 2017) |
| " In this study, we evaluated the effect of melatonin on the genotoxic activity of irinotecan in healthy human lymphocytes and a lung cancer cell line (A549) and a colorectal adenocarcinoma cell line (HT29) in vitro." | 3.79 | The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells. ( Kontek, R; Nowicka, H, 2013) |
| "On the basis of the demonstrated existence of immunoneuroendocrine interactions and on the previously observed synergistic action between the pineal hormone melatonin (MLT) and interleukin-2 (IL-2), we have designed a neuroimmunotherapeutic combination consisting of low-dose IL-2 and MLT in the treatment of advanced solid neoplasms." | 3.68 | Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results. ( Ardizzoia, A; Barni, S; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rovelli, F; Tancini, G, 1993) |
| "Analysis of residual tumor further revealed the depressed activity of MAPK, NF-kappa B, Wnt, and Hedgehog pathways and upregulated P53 pathway in tumors, which was in line with the inhibited tumor growth." | 3.01 | Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development. ( Abay, B; Chen, G; Chen, X; Fan, L; Hao, B; Li, M; Lin, S; Reiter, RJ; Ren, Y; Shi, Y; Xu, X; Yue, L; Zhang, M; Zheng, T, 2021) |
| "Melatonin is a serotonin-derived pineal gland hormone with many biological functions like regulating the sleep-wake cycle, circadian rhythm, menstrual cycle, aging, immunity, and antioxidants." | 3.01 | Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin. ( Almalki, WH; Chellappan, DK; Dua, K; Fuloria, NK; Fuloria, S; Gupta, G; Haniffa, SM; Jha, NK; Negi, P; Priya, S; Rohilla, S; Sekar, M; Singh, M; Singh, SK; Subramaniyan, V, 2023) |
| "Lung cancer is the second most common cancer and the most lethal cancer worldwide." | 2.82 | Potential role of melatonin in prevention and treatment of lung cancer. ( Chok, KC; Chye, SM; Koh, RY; Ng, KY; Ngai, ZN, 2022) |
| "Melatonin was given orally at 20 mg/day in the evening for at least 2 months." | 2.70 | Anti-angiogenic activity of melatonin in advanced cancer patients. ( Bucovec, R; Conti, A; Lissoni, P; Maestroni, GJ; Malugani, F; Rovelli, F, 2001) |
| "The possibility of natural cancer therapy has been recently suggested by advances in the knowledge of tumor immunobiology." | 2.69 | Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms. ( Giani, L; Lissoni, P; Rovelli, F; Trabattoni, P; Zerbini, S, 1998) |
| "Melatonin (MLT) has been proven to counteract chemotherapy toxicity, by acting as an anti-oxidant agent, and to promote apoptosis of cancer cells, so enhancing chemotherapy cytotoxicity." | 2.69 | Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status. ( Ardizzoia, A; Barni, S; Lissoni, P; Longarini, R; Malugani, F; Mandalà, M; Paolorossi, F; Tancini, G; Vaghi, M, 1999) |
| "Melatonin is a hormone synthesized in the pineal gland and has widespread physiological and pharmacological functions." | 1.72 | Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis. ( Duan, H; Duan, W; Li, X; Lu, G; Shao, C; Wang, J; Wang, Y; Wang, Z; Xie, M; Yan, X; Yu, W, 2022) |
| "Melatonin shows promise in the treatment of lung cancer stemness and deserves further study." | 1.51 | Melatonin reduces lung cancer stemness through inhibiting of PLC, ERK, p38, β-catenin, and Twist pathways. ( Chao, CC; Chen, PC; Chiou, PC; Huang, WC; Liu, PY; Tang, CH; Yang, YC, 2019) |
| "Melatonin was proven to possess anticancer actions, whereas its effect on NSCLC and underlying mechanisms remains poorly understood." | 1.51 | Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment. ( Di, S; Guo, K; Han, J; Li, W; Li, X; Liu, D; Ma, Z; Xu, L; Yan, X; Zhang, J; Zhang, Z; Zhu, Y, 2019) |
| "Melatonin shows therapeutic benefits in gastric cancer, but the mechanism underlying its anticancer effects remains elusive." | 1.51 | Melatonin inhibits lung metastasis of gastric cancer in vivo. ( Chen, C; Hou, D; Huang, H; Kang, L; Wang, B; Wang, X; You, R; Zhan, W; Zhang, S, 2019) |
| "Treatment with melatonin effectively increased the berberine-mediated inhibitions of cell proliferation, colony formation and cell migration, thereby enhancing the sensitivities of lung cancer cells to berberine." | 1.43 | Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells. ( Deng, W; Fu, L; Huang, W; Lu, JJ; Qin, L; Shi, D; Tang, Z; Wang, J; Xiao, X; Xie, F; Yu, Z; Zhang, C, 2016) |
| "Melatonin treatment also influenced the expression of HDAC-related molecules (HDAC1 and Ac-histone H3), upregulated the apoptosis-related molecules (PUMA and Bax), and downregulated the proliferation-related molecule (PCNA) and the anti-apoptosis-related molecule (Bcl2)." | 1.42 | HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways. ( Di, S; Fan, C; Jiang, S; Li, T; Li, W; Li, X; Ma, Z; Pan, Y; Reiter, RJ; Yan, X; Yang, Y; Zhang, Z, 2015) |
| "Melatonin was tested on the cell line only after 24 h incubation (direct effect), and on the co-culture system of SK-LU-1 and PBMC to investigate any indirect effect." | 1.40 | Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells. ( Barusrux, S; Johns, NP; Khamphio, M; Plaimee, P; Weerapreeyakul, N, 2014) |
| "Treatment with melatonin prior to irradiation did not produce any significant change in apoptosis." | 1.40 | CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells. ( Jeong, JW; Kim, JE; Kim, W, 2014) |
| "Treatment with melatonin dose-dependently decreased the viability of H1975 cells harbouring the T790M somatic mutation compared to HCC827 cells with an EGFR active mutation." | 1.40 | Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib. ( Kim, EO; Kim, J; Kim, JH; Kim, SH; Lee, D; Lee, H; Lee, J; Yun, M, 2014) |
| "Melatonin is an indolamine that is synthesized in the pineal gland and shows a wide range of physiological functions." | 1.38 | Melatonin suppresses doxorubicin-induced premature senescence of A549 lung cancer cells by ameliorating mitochondrial dysfunction. ( Jee, HJ; Kim, AJ; Kim, HJ; Kim, M; Song, N; Yoo, YH; Yun, J, 2012) |
| " Antitumor and antioxidant effect of relatively low dosage of melatonin appeared to be more effective than those of a larger one." | 1.33 | [Melatonin inhibits urethane-induced carcinogenesis tumors in murine lung]. ( Anisimov, VN; Plotnikova, NA; Semenchenko, AV; Vesnushkin, GM, 2006) |
| "The study was performed on metastatic renal cell cancer patients." | 1.30 | Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients. ( Fumagalli, L; Giani, L; Lissoni, P; Mandalà, M; Rovelli, F, 1998) |
| "Thrombocytopenia is a frequent haematologic complication of IL-2 immunotherapy of cancer." | 1.29 | Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin. ( Barni, S; Bregani, ER; Brivio, F; Conti, A; Lissoni, P; Maestroni, GJ; Rossini, F; Tancini, G, 1995) |
| "Melatonin was injected s." | 1.29 | Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice. ( Conti, A; Covacci, V; Maestroni, GJ, 1994) |
| "Melatonin was given intramuscularly at a daily dose of 20 mg at 3." | 1.28 | Endocrine and immune effects of melatonin therapy in metastatic cancer patients. ( Barni, S; Crispino, S; Fraschini, F; Lissoni, P; Tancini, G, 1989) |
| "Breast cancer, lung carcinoma, and colorectum cancer were the three neoplasms detected in the patients investigated." | 1.27 | A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations. ( Barni, S; Cattaneo, G; Crispino, S; Esposti, D; Esposti, G; Ferri, L; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1988) |
| "Melatonin serum levels were measured by radioimmunoassay before and 28 days after each cycle of chemotherapy." | 1.27 | Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients. ( Barni, S; Cattaneo, G; Crispino, S; Fraschini, F; Lissoni, P; Paolorossi, F; Rovelli, F; Tancini, G, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (7.69) | 18.7374 |
| 1990's | 19 (29.23) | 18.2507 |
| 2000's | 7 (10.77) | 29.6817 |
| 2010's | 22 (33.85) | 24.3611 |
| 2020's | 12 (18.46) | 2.80 |
| Authors | Studies |
|---|---|
| Li, M | 2 |
| Hao, B | 2 |
| Zhang, M | 1 |
| Reiter, RJ | 5 |
| Lin, S | 2 |
| Zheng, T | 2 |
| Chen, X | 2 |
| Ren, Y | 2 |
| Yue, L | 1 |
| Abay, B | 2 |
| Chen, G | 2 |
| Xu, X | 2 |
| Shi, Y | 1 |
| Fan, L | 2 |
| Liu, W | 1 |
| Tang, P | 1 |
| Wang, J | 3 |
| Ye, W | 1 |
| Ge, X | 1 |
| Rong, Y | 1 |
| Ji, C | 1 |
| Wang, Z | 2 |
| Bai, J | 1 |
| Fan, J | 1 |
| Yin, G | 1 |
| Cai, W | 1 |
| Liu, H | 2 |
| Wang, F | 1 |
| Zhao, J | 1 |
| Zhang, X | 1 |
| Zeng, Z | 1 |
| Wang, S | 2 |
| Guan, J | 1 |
| Qin, H | 1 |
| He, L | 1 |
| Fan, Y | 1 |
| Zhang, Y | 2 |
| Tu, T | 1 |
| Zhang, Q | 3 |
| Yuan, F | 1 |
| Cheng, C | 1 |
| Wang, Y | 2 |
| Shao, C | 1 |
| Lu, G | 1 |
| Xie, M | 1 |
| Duan, H | 1 |
| Li, X | 5 |
| Yu, W | 1 |
| Duan, W | 1 |
| Yan, X | 4 |
| Ngai, ZN | 1 |
| Chok, KC | 1 |
| Ng, KY | 1 |
| Koh, RY | 1 |
| Chye, SM | 1 |
| Sun, Q | 1 |
| Zhang, J | 2 |
| Yang, G | 1 |
| Cheng, S | 1 |
| Guo, D | 1 |
| Sun, F | 1 |
| Zhao, F | 1 |
| Yang, D | 1 |
| Wang, T | 1 |
| Liu, S | 1 |
| Zou, L | 1 |
| Rohilla, S | 1 |
| Singh, M | 1 |
| Priya, S | 1 |
| Almalki, WH | 1 |
| Haniffa, SM | 1 |
| Subramaniyan, V | 1 |
| Fuloria, S | 1 |
| Fuloria, NK | 1 |
| Sekar, M | 1 |
| Singh, SK | 1 |
| Jha, NK | 1 |
| Chellappan, DK | 1 |
| Negi, P | 1 |
| Dua, K | 1 |
| Gupta, G | 1 |
| Alvarez-Artime, A | 1 |
| Cernuda-Cernuda, R | 1 |
| Cepas, V | 1 |
| Gonzalez-Menendez, P | 1 |
| Fernadez-Vega, S | 1 |
| Quiros-Gonzalez, I | 1 |
| Sainz, RM | 1 |
| Mayo, JC | 1 |
| Liu, PI | 2 |
| Chang, AC | 1 |
| Lai, JL | 1 |
| Lin, TH | 1 |
| Tsai, CH | 1 |
| Chen, PC | 3 |
| Jiang, YJ | 1 |
| Lin, LW | 1 |
| Huang, WC | 2 |
| Yang, SF | 2 |
| Tang, CH | 3 |
| Sheikholeslami, S | 1 |
| Aryafar, T | 1 |
| Abedi-Firouzjah, R | 1 |
| Banaei, A | 1 |
| Dorri-Giv, M | 1 |
| Zamani, H | 1 |
| Ataei, G | 1 |
| Majdaeen, M | 1 |
| Farhood, B | 1 |
| Li, D | 1 |
| Bai, Y | 1 |
| Chang, WP | 1 |
| Lin, CC | 1 |
| Yang, YC | 2 |
| Chiou, PC | 2 |
| Liu, PY | 1 |
| Chao, CC | 2 |
| Hsu, CJ | 1 |
| Ma, Z | 3 |
| Liu, D | 2 |
| Di, S | 3 |
| Zhang, Z | 2 |
| Li, W | 2 |
| Xu, L | 1 |
| Guo, K | 1 |
| Zhu, Y | 1 |
| Han, J | 2 |
| Wang, X | 1 |
| Wang, B | 1 |
| Zhan, W | 1 |
| Kang, L | 1 |
| Zhang, S | 1 |
| Chen, C | 1 |
| Hou, D | 1 |
| You, R | 1 |
| Huang, H | 1 |
| Zhou, Q | 2 |
| Gui, S | 1 |
| Plaimee, P | 4 |
| Khamphio, M | 1 |
| Weerapreeyakul, N | 3 |
| Barusrux, S | 3 |
| Johns, NP | 3 |
| Kim, W | 1 |
| Jeong, JW | 1 |
| Kim, JE | 1 |
| Yun, M | 1 |
| Kim, EO | 1 |
| Lee, D | 1 |
| Kim, JH | 1 |
| Kim, J | 1 |
| Lee, H | 1 |
| Lee, J | 1 |
| Kim, SH | 1 |
| Thumanu, K | 1 |
| Tanthanuch, W | 1 |
| Sookprasert, A | 1 |
| Phunmanee, A | 1 |
| Pongthai, P | 1 |
| Cheawchanwattana, A | 1 |
| Johns, J | 1 |
| Konsil, J | 1 |
| Porasuphatana, S | 1 |
| Jitpimolmard, S | 1 |
| Fan, C | 2 |
| Pan, Y | 1 |
| Yang, Y | 2 |
| Jiang, S | 1 |
| Li, T | 1 |
| Lu, JJ | 1 |
| Fu, L | 1 |
| Tang, Z | 1 |
| Zhang, C | 1 |
| Qin, L | 1 |
| Yu, Z | 1 |
| Shi, D | 1 |
| Xiao, X | 1 |
| Xie, F | 1 |
| Huang, W | 1 |
| Deng, W | 1 |
| Wang, D | 1 |
| Hu, W | 1 |
| Hu, S | 1 |
| Shen, G | 2 |
| Yin, S | 2 |
| Xu, W | 1 |
| Hu, B | 2 |
| Siegfried, JM | 1 |
| Mazzoccoli, G | 5 |
| Sothern, RB | 3 |
| Pazienza, V | 2 |
| Piepoli, A | 2 |
| Muscarella, LA | 2 |
| Giuliani, F | 3 |
| Tarquini, R | 2 |
| Durfort, T | 1 |
| Francois, JC | 1 |
| Song, N | 1 |
| Kim, AJ | 1 |
| Kim, HJ | 1 |
| Jee, HJ | 1 |
| Kim, M | 1 |
| Yoo, YH | 1 |
| Yun, J | 1 |
| Kontek, R | 1 |
| Nowicka, H | 1 |
| Lissoni, P | 17 |
| Chilelli, M | 2 |
| Villa, S | 1 |
| Cerizza, L | 1 |
| Tancini, G | 13 |
| Carughi, S | 1 |
| De Cata, A | 1 |
| La Viola, M | 1 |
| Vendemiale, G | 1 |
| Vesnushkin, GM | 1 |
| Plotnikova, NA | 1 |
| Semenchenko, AV | 1 |
| Anisimov, VN | 1 |
| Hu, SL | 1 |
| Wang, WD | 1 |
| Xu, WP | 1 |
| Wang, H | 1 |
| Norsa, A | 1 |
| Martino, V | 1 |
| Bregani, ER | 1 |
| Rossini, F | 1 |
| Barni, S | 12 |
| Brivio, F | 3 |
| Conti, A | 6 |
| Maestroni, GJ | 6 |
| Meregalli, S | 1 |
| Fossati, V | 1 |
| Paolorossi, F | 7 |
| Frigerio, F | 1 |
| Giraldi, T | 2 |
| Perissin, L | 2 |
| Zorzet, S | 2 |
| Rapozzi, V | 2 |
| Covacci, V | 1 |
| Ardizzoia, A | 7 |
| Ricci, G | 1 |
| Aldeghi, R | 1 |
| Tisi, E | 3 |
| Rovelli, F | 9 |
| Rescaldani, R | 2 |
| Mancuso, M | 1 |
| Bartsch, C | 1 |
| Kvetnoy, I | 1 |
| Kvetnaia, T | 1 |
| Bartsch, H | 1 |
| Molotkov, A | 1 |
| Franz, H | 1 |
| Raikhlin, N | 1 |
| Mecke, D | 1 |
| Moulder, JE | 1 |
| Giani, L | 3 |
| Zerbini, S | 1 |
| Trabattoni, P | 1 |
| Mandalà, M | 3 |
| Malugani, F | 3 |
| Ghielmini, M | 1 |
| Pagani, O | 1 |
| de Jong, J | 1 |
| Pampallona, S | 1 |
| Maestroni, G | 1 |
| Sessa, C | 1 |
| Cavalli, F | 1 |
| Mocchegiani, E | 1 |
| Santarelli, L | 1 |
| Tibaldi, A | 1 |
| Giacconi, R | 1 |
| Bulian, D | 1 |
| Vaghi, M | 1 |
| Longarini, R | 1 |
| Fumagalli, L | 1 |
| Bucovec, R | 1 |
| Lapin, V | 1 |
| Ebels, I | 1 |
| Raĭkhlin, NT | 1 |
| Kvetnoĭ, IM | 1 |
| Ballabio, D | 1 |
| Benenti, C | 1 |
| Angeli, M | 1 |
| Viviani, S | 1 |
| Bidoli, P | 1 |
| Spinazzé, S | 1 |
| Crispino, S | 4 |
| Archili, C | 1 |
| De Toma, D | 1 |
| Pipino, G | 1 |
| Fraschini, F | 2 |
| Esposti, D | 1 |
| Ferri, L | 1 |
| Cattaneo, G | 2 |
| Esposti, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomised Double-blind Placebo-controlled Trial on Encapsulated Lemon Balm Efficacy and Tolerance on Sleep Quality Changes, and Mood and Wellbeing Effects Using Objective and Subjective Measures[NCT05422599] | 99 participants (Actual) | Interventional | 2022-05-05 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for melatonin and Lung Neoplasms
| Article | Year |
|---|---|
Potential role of melatonin in prevention and treatment of lung cancer.
Topics: Antineoplastic Agents; Circadian Rhythm; Humans; Lung Neoplasms; Melatonin; Pineal Gland; Receptors, | 2022 |
Exploring the Mechanical Perspective of a New Anti-Tumor Agent: Melatonin.
Topics: Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Female; Humans; Kidney Neoplasms; Lung Neoplasms; | 2023 |
The role of melatonin on radiation-induced pneumonitis and lung fibrosis: A systematic review.
Topics: Animals; Humans; Lung; Lung Neoplasms; Melatonin; Pneumonia; Pulmonary Fibrosis; Radiation Injuries; | 2021 |
Melatonin as a potential anticarcinogen for non-small-cell lung cancer.
Topics: Anticarcinogenic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Proliferation; Humans; Lung | 2016 |
T-helper-2 lymphocytes as a peripheral target of melatonin.
Topics: Animals; Bone Marrow; Carcinoma, Lewis Lung; Cyclophosphamide; Etoposide; Female; Granulocyte-Macrop | 1995 |
Power-frequency fields and cancer.
Topics: Animals; Breast Neoplasms; Cell Division; Chromosome Aberrations; Electromagnetic Fields; Environmen | 1998 |
15 trials available for melatonin and Lung Neoplasms
| Article | Year |
|---|---|
Melatonin enhances radiofrequency-induced NK antitumor immunity, causing cancer metabolism reprogramming and inhibition of multiple pulmonary tumor development.
Topics: Adult; Aged; Aged, 80 and over; Animals; Cell Proliferation; Combined Modality Therapy; Female; Hedg | 2021 |
Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; | 2014 |
Five years survival in metastatic non-small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antioxidants; Carcinoma, Non-Small-Cell Lung; | 2003 |
[The effect of amino acid nutritional support on serum tryptophan and melatonin in lung cancer patients receiving chemotherapy].
Topics: Aged; Amino Acids; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; C | 2006 |
Somatostatin, retinoids, melatonin, vitamin D, bromocriptine, and cyclophosphamide in chemotherapy-pretreated patients with advanced lung adenocarcinoma and low performance status.
Topics: Adenocarcinoma; Adult; Aged; Bromocriptine; Cyclophosphamide; Drug Therapy, Combination; Female; Hum | 2007 |
A randomized study of immunotherapy with low-dose subcutaneous interleukin-2 plus melatonin vs chemotherapy with cisplatin and etoposide as first-line therapy for advanced non-small cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Cisplat | 1994 |
A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Colorec | 1994 |
A randomized study of chemotherapy with cisplatin plus etoposide versus chemoendocrine therapy with cisplatin, etoposide and the pineal hormone melatonin as a first-line treatment of advanced non-small cell lung cancer patients in a poor clinical state.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cel | 1997 |
Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Topics: Adjuvants, Immunologic; Aged; Aged, 80 and over; Aloe; Brain Neoplasms; Breast Neoplasms; Drug Thera | 1998 |
Chemoneuroendocrine therapy of metastatic breast cancer with persistent thrombocytopenia with weekly low-dose epirubicin plus melatonin: a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Neoplasms; Breast Neoplasms | 1999 |
Double-blind randomized study on the myeloprotective effect of melatonin in combination with carboplatin and etoposide in advanced lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Diseases; Carboplatin; Carc | 1999 |
Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dr | 1999 |
Anti-angiogenic activity of melatonin in advanced cancer patients.
Topics: Adult; Aged; Bone Neoplasms; Carcinoma; Carcinoma, Hepatocellular; Carcinoma, Non-Small-Cell Lung; C | 2001 |
Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Topics: Biopterins; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; Drug Administration Schedule; | 1992 |
Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Topics: Adult; Aged; Carcinoma, Non-Small-Cell Lung; Cisplatin; Drug Resistance; Humans; Lung Neoplasms; Mel | 1992 |
44 other studies available for melatonin and Lung Neoplasms
| Article | Year |
|---|---|
Extracellular vesicles derived from melatonin-preconditioned mesenchymal stem cells containing USP29 repair traumatic spinal cord injury by stabilizing NRF2.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Extracellular Vesicles; Lung Neoplasms; Melatonin; Mesenchy | 2021 |
The effect and mechanisms of melatonin on the proliferation and apoptosis of lung cancer cells.
Topics: A549 Cells; Apoptosis; Cell Proliferation; Humans; Lung Neoplasms; MAP Kinase Signaling System; Mela | 2022 |
Single-cell transcriptomic analysis reveals circadian rhythm disruption associated with poor prognosis and drug-resistance in lung adenocarcinoma.
Topics: Adenocarcinoma of Lung; Circadian Rhythm; Humans; Lung Neoplasms; Melatonin; Prognosis; Transcriptom | 2022 |
Melatonin may suppress lung adenocarcinoma progression via regulation of the circular noncoding RNA hsa_circ_0017109/miR-135b-3p/TOX3 axis.
Topics: Adenocarcinoma of Lung; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Diseas | 2022 |
The ubiquitin-specific protease 8 antagonizes melatonin-induced endocytic degradation of MT
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Animals; Humans; Lung Neoplasms; Melatonin; Receptor, Melato | 2022 |
Melatonin-Induced Cytoskeleton Reorganization Leads to Inhibition of Melanoma Cancer Cell Proliferation.
Topics: Actins; Animals; Antioxidants; Catalase; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cytosk | 2020 |
Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
Topics: Animals; Bone Marrow Cells; Bone Neoplasms; Bone Resorption; Cell Differentiation; Disease Models, A | 2021 |
Melatonin inhibits lung cancer development by reversing the Warburg effect via stimulating the SIRT3/PDH axis.
Topics: Animals; Cell Line, Tumor; Lung Neoplasms; Melatonin; Mice; Pyruvate Dehydrogenase Complex; Sirtuin | 2021 |
Relationships of salivary cortisol and melatonin rhythms to sleep quality, emotion, and fatigue levels in patients with newly diagnosed lung cancer.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Circadian Rhythm; Depression; Fatigue; Female; | 2017 |
Melatonin reduces lung cancer stemness through inhibiting of PLC, ERK, p38, β-catenin, and Twist pathways.
Topics: A549 Cells; AC133 Antigen; beta Catenin; Carcinogenesis; Cell Line, Tumor; Humans; Lung Neoplasms; M | 2019 |
Melatonin suppresses lung cancer metastasis by inhibition of epithelial-mesenchymal transition through targeting to Twist.
Topics: A549 Cells; Animals; Antineoplastic Agents; beta Catenin; Cell Movement; Epithelial-Mesenchymal Tran | 2019 |
Histone deacetylase 9 downregulation decreases tumor growth and promotes apoptosis in non-small cell lung cancer after melatonin treatment.
Topics: A549 Cells; Animals; Apoptosis; Carcinoma, Non-Small-Cell Lung; Down-Regulation; Gene Expression Reg | 2019 |
Melatonin inhibits lung metastasis of gastric cancer in vivo.
Topics: Animals; Cell Line, Tumor; Cyclooxygenase 2; Down-Regulation; Gene Expression Regulation, Neoplastic | 2019 |
Melatonin inhibits the migration of human lung adenocarcinoma A549 cell lines involving JNK/MAPK pathway.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antioxidants; Cell Line, Tumor; Cell | 2014 |
Immunomodulatory effect of melatonin in SK-LU-1 human lung adenocarcinoma cells co-cultured with peripheral blood mononuclear cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antioxidants; Apoptosis; Cell Line, T | 2014 |
CCAR2 deficiency augments genotoxic stress-induced apoptosis in the presence of melatonin in non-small cell lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Adenocarcinoma; Antioxidants; Apoptosis; Blotting, Western; Ca | 2014 |
Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Topics: Carcinoma, Non-Small-Cell Lung; Cell Division; Cell Line, Tumor; ErbB Receptors; Flow Cytometry; Gef | 2014 |
Melatonin induces apoptosis through biomolecular changes, in SK-LU-1 human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Apoptosis; Caspase 3; Caspase 7; Cell Line, Tumor; DNA Fragmentation; Humans; Lung N | 2014 |
Melatonin potentiates cisplatin-induced apoptosis and cell cycle arrest in human lung adenocarcinoma cells.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Apoptosis; Cell Cycle Checkpoints; Ce | 2015 |
HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Apoptosis; Cell Line, Tumor; Cell Survival; Glutathione; His | 2015 |
Melatonin inhibits AP-2β/hTERT, NF-κB/COX-2 and Akt/ERK and activates caspase/Cyto C signaling to enhance the antitumor activity of berberine in lung cancer cells.
Topics: Active Transport, Cell Nucleus; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2016 |
Melatonin and tryptophan circadian profiles in patients with advanced non-small cell lung cancer.
Topics: Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Circadian Rhythm; | 2009 |
Early changes in pulmonary gene expression following tobacco exposure shed light on the role of estrogen metabolism in lung carcinogenesis.
Topics: Alcohol Oxidoreductases; Animals; Aryl Hydrocarbon Hydroxylases; Cell Transformation, Neoplastic; Ci | 2010 |
Circadian aspects of growth hormone-insulin-like growth factor axis function in patients with lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous | 2012 |
Alteration of hypothalamic-pituitary-thyroid axis function in non-small-cell lung cancer patients.
Topics: Adult; Carcinoma, Non-Small-Cell Lung; Case-Control Studies; Circadian Rhythm; Female; Humans; Hypot | 2012 |
Chronodisruption in lung cancer and possible therapeutic approaches.
Topics: Adenocarcinoma; Adult; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Chronobiology Disor | 2011 |
Determination of whole body circadian phase in lung cancer patients: melatonin vs. cortisol.
Topics: Adult; Aged; Case-Control Studies; Circadian Rhythm; Humans; Hydrocortisone; Lung Neoplasms; Male; M | 2012 |
Melatonin suppresses doxorubicin-induced premature senescence of A549 lung cancer cells by ameliorating mitochondrial dysfunction.
Topics: Antibiotics, Antineoplastic; CDC2 Protein Kinase; Cell Line, Tumor; Cellular Senescence; Cyclin B; C | 2012 |
The modulatory effect of melatonin on genotoxicity of irinotecan in healthy human lymphocytes and cancer cells.
Topics: Adenocarcinoma; Adult; Antimutagenic Agents; Antineoplastic Agents, Phytogenic; Camptothecin; Carcin | 2013 |
Melatonin and cortisol serum levels in lung cancer patients at different stages of disease.
Topics: Aged; Circadian Rhythm; Humans; Hydrocortisone; Lung Neoplasms; Melatonin; Neoplasm Staging; Referen | 2005 |
[Melatonin inhibits urethane-induced carcinogenesis tumors in murine lung].
Topics: Adenoma; Animals; Antineoplastic Agents; Antioxidants; Biomarkers, Tumor; Catalase; Lung Neoplasms; | 2006 |
Prevention of interleukin-2-induced thrombocytopenia during the immunotherapy of cancer by a concomitant administration of the pineal hormone melatonin.
Topics: Adult; Aged; Blood Platelets; Drug Therapy, Combination; Female; Humans; Interleukin-2; Interleukin- | 1995 |
Stress, melatonin and tumor progression in mice.
Topics: Animals; Circadian Rhythm; Electric Stimulation; Female; Light; Lung Neoplasms; Melatonin; Mice; Mic | 1994 |
Hematopoietic rescue via T-cell-dependent, endogenous granulocyte-macrophage colony-stimulating factor induced by the pineal neurohormone melatonin in tumor-bearing mice.
Topics: Animals; Apoptosis; Bone Marrow; Cyclophosphamide; Etoposide; Female; Granulocyte-Macrophage Colony- | 1994 |
Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Topics: Adult; Aged; Biopterins; Breast Neoplasms; Colonic Neoplasms; Drug Therapy, Combination; Eosinophils | 1993 |
Nocturnal urinary 6-sulfatoxymelatonin and proliferating cell nuclear antigen-immunopositive tumor cells show strong positive correlations in patients with gastrointestinal and lung cancer.
Topics: Adenocarcinoma; Aged; Carcinoma, Squamous Cell; Gastrointestinal Neoplasms; Humans; Immunoenzyme Tec | 1997 |
Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2.
Topics: Animal Feed; Animals; Corticosterone; Disease Progression; Feces; Female; Interleukin-2; Lung Neopla | 1999 |
Immunomodulatory effects of IL-12 in relation to the pineal endocrine function in metastatic cancer patients.
Topics: Adjuvants, Immunologic; Carcinoma, Renal Cell; Humans; Immunity, Innate; Immunotherapy; Inflammation | 1998 |
Effects of some low molecular weight sheep pineal fractions and melatonin on different tumors in rats and mice.
Topics: Animals; Female; Lung Neoplasms; Male; Melatonin; Methylcholanthrene; Mice; Molecular Weight; Neopla | 1976 |
[Dynamics of changes in enterochromaffin cells during tumor growth].
Topics: Chromaffin System; Enterochromaffin Cells; Gastrointestinal Neoplasms; Humans; Hyperplasia; Leukemia | 1976 |
Normalization of the light/dark rhythm of melatonin after prolonged subcutaneous administration of interleukin-2 in advanced small cell lung cancer patients.
Topics: Carcinoma, Small Cell; Circadian Rhythm; Female; Humans; Injections, Subcutaneous; Interleukin-2; Li | 1992 |
Endocrine and immune effects of melatonin therapy in metastatic cancer patients.
Topics: Adenocarcinoma; Aged; B-Lymphocytes; beta-Endorphin; Female; Growth Hormone; Humans; Insulin-Like Gr | 1989 |
A study on the relationship between the pineal gland and the opioid system in patients with cancer. Preliminary considerations.
Topics: Adult; beta-Endorphin; Breast Neoplasms; Colonic Neoplasms; Endorphins; Female; Growth Hormone; Huma | 1988 |
Melatonin increase as predictor for tumor objective response to chemotherapy in advanced cancer patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Colonic Neoplasms; Female; Humans; | 1988 |